We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Reckitt Benckiser Ireland Limited

7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 1 468 9200
Fax: +353 1 468 9299

Summary of Product Characteristics last updated on medicines.ie: 7/13/2017
SPC Nurofen Plus

Go to top of the page

Nurofen Plus Tablets

Ibuprofen 200mg

Codeine Phosphate Hemihydrate 12.8mg

Go to top of the page

Each tablet contains Ibuprofen 200.0 mg and Codeine Phosphate Hemihydrate 12.8 mg.

For a full list of excipients, see section 6.1.

Go to top of the page

Film-coated Tablet (Tablet)

Nurofen Plus is a white film coated, biconvex capsule-shaped tablet embossed with the logo 'N+' on one side.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

For the relief of pain in such conditions as: rheumatic and muscular pain, backache, migraine, dental pain, dysmenorrhoea, feverishness, symptoms of cold and flu.

This product is indicated in patients older than 12 years of age for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen alone.

Go to top of the page
4.2 Posology and method of administration


Codeine should be used at the lowest effective dose for the shortest period of time. This dose may be taken up to 4 times daily at intervals of not less than 6 hours. The maximum daily dose should not exceed 6 tablets in 24 hours.

The duration of treatment should be limited to 3 days and if no effective pain relief is achieved the patients/carers should be advised to seek the views of a physician.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).

Adults, the elderly and children over 12 years;

Initially two tablets, then if necessary one or two tablets every 6 hours.

Paediatric population:

Children aged less than 12 years:

Ibuprofen + Codeine combination solid dose strength products should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see sections 4.3 & 4.4).

Nurofen Plus is contraindicated in children below the age of 12 years for the symptomatic treatment of cough and/or cold (see section 4.3).

Children aged 12 years to 18 years:

Nurofen Plus is not recommended for use in children aged 12 years to 18 years with compromised respiratory function for the symptomatic treatment of cough and or cold (see section 4.4)


No special dosage modifications are required for elderly patients, unless renal or hepatic function is impaired, in which case dosage should be assessed individually. NSAIDs should not be used continuously over prolonged periods in the elderly for the management of arthroses without careful supervision.

Method of administration

For oral administration.

Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substances or any of the excipients listed in section 6.1.

Patients who have previously shown hypersensitivity reactions (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) in response to Ibuprofen, Acetylsalicylic Acid (Aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs).

Severe liver or kidney failure (see section 4.4).

Severe heart failure (NYHA Class IV).

History of gastrointestinal bleeding or perforation related to previous NSAIDs therapy.

Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).

Respiratory depression

Chronic constipation

Last trimester of pregnancy (See section 4.6 Pregnancy and Lactation)

Concomitant treatment with Monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment (see section 4.5).

Use of codeine containing products is contraindicated in women during breastfeeding (see section 4.6).

In all paediatric patients (0-18 years of age) who undergo tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome due to an increased risk of developing serious and life-threatening adverse reactions (see section 4.4).

In children below the age of 12 years for the symptomatic treatment of cough and or cold due to an increased risk of developing serious and life-threatening adverse reactions.

In patients for whom it is known they are CYP2D6 ultra-rapid metabolisers.

Go to top of the page
4.4 Special warnings and precautions for use

Undesirable effects may be minimised by using the minimum effective dose for the shortest duration necessary to control symptoms (See section 4.2, and GI and cardiovascular risks below).

Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2)

Gastrointestinal effects: NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's Disease) as their condition may be exacerbated (see section 4.8 – undesirable effects).

GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without any warning symptoms or a previous history of serious GI events.

The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and 4.5).

Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.

Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5).

When GI bleeding or ulceration occurs in patients receiving Nurofen Plus, the treatment should be withdrawn.

Nurofen Plus tablets should be used with caution in patients with gastrointestinal disease. In patients receiving anti-coagulant therapy, prothrombin time should be monitored daily for the first few days of combined treatment.

Cardiovascular and cerebrovascular effects: Caution (discussion with doctor or pharmacist) is required prior to starting treatment in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with NSAID therapy.

Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤ 1200mg/day) is associated with an increased risk of arterial thrombotic events.

Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg/day) should be avoided.

Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of ibuprofen (2400 mg/day) are required

The tablets should be used with caution in patients with raised intracranial pressure or head injury.

Respiratory: Bronchospasm may be precipitated in patients suffering from or with a history of bronchial asthma or allergic disease. The possibility of cross-sensitivity with aspirin and other non-steroidal anti-inflammatory agents should be considered. If symptoms persist, consult your doctor.

Other NSAIDs: The use of Nurofen Plus with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided (see section 4.5).

SLE and mixed connective tissue disease: There is an increased risk of aseptic meningitis in patients with Systemic lupus erythematoses and mixed connective tissue disease using the active ingredients in this product (see section 4.8).

Renal: Renal impairment as renal function may deteriorate (see section 4.3 and 4.8). There is a risk of renal impairment in dehydrated children and adolescents.

Hepatic: Hepatic dysfunction (see section 4.3 and 4.8)

Dermatological effects: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Nurofen Plus should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Exceptionally, varicella can be at the origin of serious cutaneous and soft tissue infectious complications. To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of Nurofen Plus Tablets in case of varicella.

Impaired female fertility: There is some evidence that drugs which inhibit cyclo-oxygenase/prostaglandin synthesis may cause impairment of female fertility by an effect on ovulation. This is reversible on withdrawal of treatment.

Do not take concurrently with any other codeine containing compounds.

Care is advised in the administration of codeine to patients with hypotension, hypothyroidism, adrenocortical insufficiency, shock, obstructive bowel disorders, acute abdominal conditions (e.g. peptic ulcer), recent gastrointestinal surgery, gallstones, myasthenia gravis, and a history of peptic ulcer or convulsions and also in patients with a history of drug abuse.

Elderly patients may metabolise or eliminate opioid analgesics more slowly than younger adults. Codeine should be used with caution in the elderly and debilitated patients as they may be more susceptible to the respiratory depressant effects.

Codeine is a narcotic analgesic. No more than the stated dose of this medicine should be taken. Prolonged regular use, except under medical supervision, may lead to physical and psychological dependence (addiction) and result in withdrawal symptoms, such as restlessness and irritability once the drug is stopped. It is important to consult a doctor if a patient experiences the need to use this product all the time.

If you are pregnant or are being prescribed medicines, seek the advice of a doctor before taking this product (see section 4.3).

CYP2D6 metabolism: Codeine is metabolised by the liver enzyme CYP2D6 into morphine, its active metabolite. If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect will not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an extensive or ultra-rapid metaboliser there is an increased risk of developing side effects of opioid toxicity even at commonly prescribed doses. These patients convert codeine into morphine rapidly resulting in higher than expected serum morphine levels.

General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation, and lack of appetite. In severe cases this may include symptoms of circulatory and respiratory depression, which may be life-threatening and very rarely fatal. Estimates of prevalence of ultra-rapid metabolisers in different populations are summarized below:


Prevalence %



African American

3.4% to 6.5%


1.2% to 2%


3.6% to 6.5%





Northern European

1 to 2%

Post-operative use in children: There have been reports in the published literature that codeine given post-operatively in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnoea, led to rare, but life-threatening adverse events including death (see also section 4.3). All children received doses of codeine that were within the appropriate dose range; however there was evidence that these children were either ultra-rapid or extensive metabolisers in their ability to metabolise codeine to morphine.

Children with compromised respiratory function: Codeine is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures. These factors may worsen symptoms of morphine toxicity.

Keep out of the sight and reach of children.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

If you are elderly or particularly if you are receiving regular treatment from your doctor, consult your doctor before taking this medicine.

The following drug-drug interactions are known to occur in association with the ibuprofen active substance in the product.

Ibuprofen (like other NSAIDs) should not be used in combination with:

Acetylsalicylic acid (aspirin): unless low-dose aspirin (not above 75mg daily) has been advised by a doctor, as this may increase the risk of adverse reactions especially in the gastrointestinal tract (see section 4.4). Concomitant administration of ibuprofen and acetylsalicylic acid is not generally recommended because of the potential of increased adverse effects.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded.No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1)

Other NSAIDs including cyclooxygenase-2 selective-inhibitors: Avoid concomitant use of two or more NSAIDs as this may increase the risk of adverse effects (see section 4.4).

The product should be used with caution in combination with:

Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4)

Antihypertensives (ACE inhibitors and Angiotensin II Antagonists) and diuretics: NSAIDs may diminish the effects of these drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking a cyclooxygenase-2 selective inhibitors concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter. Diuretics can increase the risk of nephrotoxicity of NSAIDs. The hypotensive actions of diuretics and anti-hypertensive agents may be potentiated when used concurrently with opioid analgesics.

Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4).

Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4)

Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.

Lithium: there is evidence for potential increases in plasma levels of lithium.

Methotrexate: there is evidence for potential increases in plasma levels of methotrexate.

Ciclosporin: Increased risk of nephrotoxicity.

Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.

Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus.

Zidovudine: Increased risk of haematological toxicity when NSAIDs are given with Zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in HIV(+) haemophiles receiving concurrent treatment with zidovudine and ibuprofen.

Quinolone antibiotics: Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.

The following drug-drug interactions are known to occur in association with the Codeine active substance in the product:

Monoamine oxidase inhibitors: CNS depression or excitation may occur if codeine is given to patients receiving monoamine oxidase inhibitors, or within two weeks of stopping treatment with them (see section 4.3).

Moclobemide: risk of hypertensive crisis.

Hydroxyzine: Concurrent use of hydroxyzine (anxiolytics) with codeine may result in increased analgesia as well as increased CNS depressant, sedative and hypotensive effects.

Central Nervous System Depressants: The depressant effects of codeine are enhanced by depressants of the central nervous system such as alcohol, anaesthetics, hypnotics, sedatives, tricyclic antidepressants or antipsychotics and phenothiazines.

Antidiarrhoeal and Anti-peristaltic agents: Concurrent use of codeine with antidiarrhoeal and antiperistaltic agents such as loperamide and kaolin may increase the risk of severe constipation.

Antimuscarinics: Concomitant use of antimuscarinics or medications with muscarinic action, e.g., atropine and some antidepressants may result in an increased risk of severe constipation which may lead to paralytic ileus and/or urinary retention.

Neuromuscular Blocking Agents: The respiratory depressant effect caused by neuromuscular blocking agents may be additive to the central respiratory depressant effects of opioid analgesics.

Quinidine: Quinidine can inhibit the analgesic effect of codeine.

Mexiletine: Codeine may delay the absorption of mexiletine and thus reduce the antiarrhythmic effect of the latter.

Metoclopramide, cisapride and domperidone: Codeine may antagonise the gastrointestinal effects of metoclopramide, cisapride and domperidone.

Cimetidine: Cimetidine inhibits the metabolism of opioid analgesics resulting in increased plasma concentrations.

Naxolone: Naxolone antagonises the analgesic, CNS and respiratory depressant effects of opioid analgesics. Naltrexone also blocks the therapeutic effect of opioids.

Interference with laboratory tests: Opioid analgesics interfere with a number of laboratory tests including plasma amylase, lipase, bilirubin, alkaline phosphatase, lactate dehydrogenase, alanine aminotransferase and aspartate aminotransferase. Opioids may also interfere with gastric emptying studies as they delay gastric emptying and with hepatobiliary imaging using technetium Tc 99m disofenin as opioid treatment may cause constriction of the sphincter of Oddi and increase biliary tract pressure.

4.6 Fertility, pregnancy and lactation


Whilst no teratogenic effects have been demonstrated in animal experiments, the use of Nurofen Plus should, if possible, be avoided during the first six months of pregnancy. During the third trimester, Ibuprofen is contraindicated as there is a risk of premature closure of the foetal ductus arteriosus with possible persistent pulmonary hypertension. The onset of labour may be delayed and duration increased with an increased bleeding tendency in both mother and child (see section 4.3 Contraindications).


This product should not be used during breastfeeding (see section 4.3).

At normal therapeutic doses codeine and its active metabolite may be present in breast milk at very low doses and is unlikely to adversely affect the breast fed infant. However, if the patient is an ultra-rapid metaboliser of CYP2D6, higher levels of the active metabolite, morphine, may be present in breast milk and on very rare occasions may result in symptoms of opioid toxicity in the infant, which may be fatal.


See section 4.4 regarding female fertility.

Go to top of the page
4.7 Effects on ability to drive and use machines

Patients may become dizzy and sedated with Nurofen Plus Tablets. Rare side effects may include convulsions, hallucinations, blurred or double vision and orthostatic hypotension (see section 4.8). If affected, patients should not drive or operate machinery.

Go to top of the page
4.8 Undesirable effects

The list of the following adverse effects relates to those experienced with Ibuprofen and Codeine at OTC doses (maximum 1200mg ibuprofen per day), in short-term use. In the treatment of mild to moderate pain and fever. In the treatment of other indications or under long-term treatment, additional adverse effects may occur.

Adverse events which have been associated with Ibuprofen and Codeine are given below tabulated by System Organ Class (SOC) and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

System Organ Class


Adverse Events

Blood and Lymphatic System Disorders

Very rare

Haematopoietic disorders1

Immune system disorders


Hypersensitivity reactions with urticaria and pruritus2

Very rare

Severe hypersensitivity reactions. Symptoms could be: facial, tongue and throat swelling, dyspnoea, tachycardia, and hypotension (anaphylaxis, angioedema or severe shock)2

Metabolism and Nutrition Disorders

Not known

Decreased appetite

Psychiatric Disorders

Not known

Depression, hallucination, confusional state, dependence, mood altered, restlessness, nightmares.

Nervous System Disorders



Very rare

Aseptic meningitis3

Not known

Dizziness, drowsiness, convulsion, intracranial pressure increased, dyskinesia

Eye Disorders

Very rare

Vision blurred

Not known


Ear and Labyrinth disorders

Not known


Cardiac Disorders

Very rare

Cardiac failure and oedema4.

Not known

Bradycardia, palpitations

Vascular Disorders

Very rare


Not known

Orthostatic hypotension

Respiratory, Thoracic and Mediastinal Disorders

Not known

Respiratory tract reactivity comprising asthma, bronchospasm or dyspnoea2 Respiratory depression, cough suppression

Gastro-intestinal Disorders


Abdominal pain, nausea and dyspepsia .Exacerbation of colitis and Crohn's disease, gastritis5,6.


Diarrhoea, flatulence, constipation and vomiting.

Very rare

Peptic ulcer, gastrointestinal perforation or gastrointestinal haemorrhage, melaena, and haematemesis7. Mouth ulceration.

Not known

Dry mouth

Hepatobiliary Disorders

Very rare

Liver disorder8,

Not known

Biliary colic

Skin and Subcutaneous Tissue Disorders


Skin rash2

Very rare

Severe forms of skin reactions such as erythema multiforme can occur. Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrosis2.

Not known


Musculoskeletal and Connective Tissue Disorders

Not known

Muscle rigidity

Renal and Urinary Disorders

Very rare

Acute renal failure9

Not known

Ureteric colic, dysuria10.

General and Administration Site Conditions

Not known

Hypothermia, hyperhidrosis, irritability, fatigue, malaise.


Very rare

Haemogloblin decreased, urea renal clearance decreased.

Infections and infestations

Very rare

Exacerbation of infections related inflammation (e.g. development of necrotizing fasciitis), in exceptional cases, severe skin infections and soft-tissue complication may occur during a varicella infection.

Description of Selected Adverse Reactions

1 Examples include anaemia, leucopenia, thrombocytopenia, pancytopenia and agranulocytosis.

First signs are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe exhaustion, nose and skin bleeding, and bruising.

2Hypersensitivity reactions: These may consist of (a) non-specific allergic reactions and anaphylaxis, (b) respiratory tract reactivity, including asthma, aggravated asthma, bronchospasm, and dyspnoea, or (c) various skin reactions, including pruritius, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses, including toxic epidermal necrolysis, Stevens-Johnson Syndrome and erythema multiforme.

3The pathogenic mechanism of drug-induced aseptic meningitis is not fully understood. However, the available data on NSAID-related aseptic meningitis points to a hypersensitivity reaction (due to a temporal relationship with drug intake, and disappearance of symptoms after drug discontinuation). Single cases of symptoms of aseptic meningitis (such as stiff neck, headache, nausea, vomiting, fever or disorientation) have been observed during treatment with ibuprofen in patients with existing auto-immune disorders (such as systemic lupus erythematosus and mixed connective tissue disease).

4Clinical studies suggest that use of Ibuprofen, particularly at a high doses (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).

5The adverse events observed most often are gastrointestinal in nature.

6See Section 4.4.

7Sometimes fatal.

8Especially in long-term treatment.

9Especially in long-term use, associated with increased serum urea concentrations and oedema. Also includes papillary necrosis.

10Increased frequency, decrease in amount.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via

HPRA Pharmacovigilance

Earlsfort Terrace

IRL - Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.hpra.ie

e-mail: medsafety@hpra.ie

Go to top of the page
4.9 Overdose

In children, ingestion of more than 400 mg/kg ibuprofen may cause symptoms. In adults the dose response effect is less clear cut. The half-life in overdose is 1.5-3 hours. Ingestion of more than 350mg Codeine or for a child, more than 5mg Codeine per kg of bodyweight, should be considered potentially harmful. Fatalities due to codeine overdose have been reported with intakes above 500mg. Due to the relative concentrations of each active ingredient in the product and their respective toxicity thresholds, the toxic effects of codeine in overdose would be expected to occur before those of ibuprofen.


Most patients who have ingested clinically important amounts of NSAIDs will develop no more than nausea, vomiting, epigastric pain, or more rarely diarrhoea. Tinnitus, headache and gastro-intestinal irritation or bleeding are also possible. In more serious poisoning, toxicity is seen in the central nervous system, manifesting as dizziness, drowsiness, occasionally excitation and disorientation, respiratory depression, excitability, convulsions, loss of consciousness, or coma. Co-ingestion of other sedative agents, including alcohol, may exacerbate effects on the central nervous system. Occasionally patients develop convulsions. The pupils may be pin point in size. Hypotension and tachycardia are possible but unlikely. In serious poisoning metabolic acidosis may occur and the prothrombin time/INR may be prolonged, probably due to interference with the actions of circulating clotting factors. Acute renal failure and liver damage may occur. Exacerbation of asthma is possible in asthmatics.


Management should be symptomatic and supportive and include the maintenance of a clear airway and monitoring of cardiac and vital signs until stable. Consider oral administration of activated charcoal if the patient presents within 1 hour of ingestion of a potentially toxic amount, including more than 350mg Codeine or for a child, more than 5mg Codeine per kg of bodyweight. If frequent or prolonged, convulsions should be treated with intravenous diazepam or lorazepam. Give bronchodiliators for asthma.

If severe CNS depression has occurred, artificial respiration, oxygen and parenteral naloxone may be needed. Naloxone is a competitive antagonist and has a short half-life so large and repeated doses may be required in a seriously poisoned patient. Observe for at least four hours after ingestion, or eight hours if a sustained release preparation has been taken. Any imbalance in electrolyte levels should be considered.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic Group: Ibuprofen combinations; ATC Code: M01 AE51

Ibuprofen is an NSAID which acts peripherally, inhibiting prostaglandin synthesis and the action of chemical mediators of pain. In humans, ibuprofen reduces inflammatory pain, swellings and fever. Furthermore, ibuprofen reversibly inhibits platelet aggregation. Codeine is a narcotic analgesic acting on central opiate receptors, although its pharmacological effects are thought to be due largely to its biotransformation to morphine.

The combination of a well tolerated peripheral analgesic with a centrally acting analgesic provides optimum pain relief with a lower potential for producing side effects.

Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Some pharmacodynamics studies show that when single doses of ibuprofen 400mg were taken within 8 h before or within 30 min after immediate release acetylsalicylic acid dosing (81mg), a decreased effect of acetylsalicylic acid on the formation of thromboxane or platelet aggregation occurred. Although there are uncertainties regarding extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 4.5).

Codeine is a centrally acting weak analgesic. Codeine exerts its effect through μ opioid receptors, although codeine has low affinity for these receptors, and its analgesic effect is due to its conversion to morphine. Codeine, particularly in combination with other analgesics such as paracetamol, has been shown to be effective in acute nociceptive pain.

Go to top of the page
5.2 Pharmacokinetic properties

The combination of the two drugs is appropriate from a pharmacokinetic viewpoint; the tablet exhibits normal release characteristics for both active substances.

Ibuprofen is rapidly absorbed from the gastrointestinal tract following administration and is rapidly distributed throughout the whole body. It is extensively bound to plasma proteins and diffused into the synovial fluid. The excretion is rapid and complete via the kidneys.

Maximum plasma concentrations are reached 45 minutes after ingestion if taken on an empty stomach. When taken with food, peak levels are observed after one to two hours. These times may vary with different dosage forms.

The half-life of ibuprofen is about two hours.

Codeine phosphate is well absorbed after oral administration, producing peak plasma concentrations in about one hour. The plasma half-life is approximately three hours, excretion being mainly in the urine.

Go to top of the page
5.3 Preclinical safety data

Not applicable.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Tablet Core:

Microcrystalline cellulose

Sodium starch glycollate (Type A)


Pregelatinised maize starch

Film coating:



Opaspray white M-1-7111B

(containing Hypromellose and titanium dioxide (E171)).

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

3 years

Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.

Store in the original package in order to protect from light.

Go to top of the page
6.5 Nature and contents of container

Blister packs (250 micron PVC/40 gsm PVDC heat sealed to aluminium foil) containing 6, 12 or 24 tablets (OTC pack sizes).

Blister packs (250 micron PVC/40 gsm PVDC heat sealed to aluminium foil) containing 32 or 48 tablets (POM pack sizes)

Not all pack sizes may be marketed.

Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.

Go to top of the page

Reckitt Benckiser Ireland Ltd.

7 Riverwalk

Citywest Business Campus

Dublin 24

Go to top of the page

PA 979/34/1

Go to top of the page

Date of first authorisation: 21st March 1997

Date of last renewal: 21st March 2007

Go to top of the page

July 2016

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

   Codeine Phosphate Hemihydrate